This Judgment and Reasons dealt with an application for judicial review brought by Galderma in respect of a decision by the Patented Medicines Prices Review Board (the “Board”) which found that the invention of Canadian Patent 2,478,237 pertained to, or could be used for, Galderma’s product DIFFERIN.